Oncology Target Option Deal With GSK Helps Vernalis Hit Comeback Trail
This article was originally published in The Pink Sheet Daily
Executive SummaryUK biotech gets $6 million upfront, half of which is structured as an equity investment by GSK.
You may also be interested in...
Financings Of The Fortnight: Big FOPO For Troubled Alnylam, Plus First European IPO Of 2012 For Adocia
Plus news on recent financing by Satori, Ceptaris, Vernalis and Exelixis